China State FDA Issues Warning In Wake Of Heparin Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In the wake of a U.S. safety scare related to Baxter Healthcare's heparin, China's State FDA has warned foreign pharmaceutical companies to conduct business with only licensed Chinese companies